Brittney L. Dickey

Brittney L. Dickey

Auto-generated profile, based on publicly available information

Brittney L. Dickey

Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
JFJordan B Fenlon
Jordan B Fenlon
ARAnne F Rositch
Anne F Rositch
BDBrittney L Dickey
Brittney L Dickey
SKStephen Kimani
Stephen Kimani
GSGita Suneja
Gita Suneja
Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.

24 April 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
NGNancy Gillis
Nancy Gillis
BDBrittney L Dickey
Brittney L Dickey
CCChristelle Colin-Leitzinger
Christelle Colin-Leitzinger
YTYi-Han Tang
Yi-Han Tang
RPRyan M Putney
Ryan M Putney
ACAnna Elizabeth Coghill
Anna Elizabeth Coghill
Background: Cancer-related deaths for people with human immunodeficiency virus (PWH) are increasing due to longer life expectancies and disparately poor cancer-related outcomes. We hypothesize that advanced biological aging contributes to cancer-related morbidity and mortality for PWH and cancer. We sought to determine the impact of clonal hematopoiesis (CH) on cancer disparities in PWH. Methods: We conducted a retrospective study to compare the prevalence and clinical outcomes of CH in PWH and people without HIV (PWoH) and cancer. Included in the study were PWH and similar PWoH based on tumor site, age, tumor sequence, and cancer treatment status. Biological aging was also measured using epigenetic methylation clocks. Results: In 136 patients with cancer, PWH had twice the prevalence of CH compared to similar PWoH (23% vs 11%, P = .07). After adjusting for patient characteristics, PWH were 4 times more likely than PWoH to have CH (odds ratio, 4.1 [95% confidence interval, 1.3–13.9]; P = .02). The effect of CH on survival was most pronounced in PWH, who had a 5-year survival rate of 38% if they had CH (vs 59% if no CH), compared to PWoH who had a 5-year survival rate of 75% if they had CH (vs 83% if no CH). Conclusions: This study provides the first evidence that PWH may have a higher prevalence of CH than PWoH with the same cancers. CH may be an independent biological aging risk factor contributing to inferior survival for PWH and cancer.

26 May 2022 in Cancer Medicine
Verified
Journal Article
Open access
BDBrittney L. Dickey
Brittney L. Dickey
BNBelinda Nedjai
Belinda Nedjai
MPMatthew D. Preece
Matthew D. Preece
MSMichael J. Schell
Michael J. Schell
DBDavid Boulware
David Boulware
AGAnna R. Giuliano
Anna R. Giuliano
As oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) increases in men, the need for a screening test to diagnose OPC early is crucial. While HPV‐associated OPC has a favorable prognosis, recurrence is likely, and metastatic OPC is often incurable regardless of HPV status. Our previous study of pretreatment, male OPC cases (n = 101) and age‐ and smoking‐matched controls (n = 101) found methylation of the host EPB41L3 tumor suppressor gene and HPV16 in the oral gargle was correlated with these biomarkers in the tumor. Methylation of these genes in the oral gargle was significantly (p < 0.0001) higher among cases compared to controls. To further study the utility of HPV16/EPB41L3 methylation, we expanded the sample size and specifically increased the number of early OPC cases (T1‐T2, N0‐N1; small tumors with a single ipsilateral node <3 cm) to evaluate these biomarkers in early and late OPC. This study included 228 OPC cases, 92 of which were early cases and frequency matched to 142 healthy controls. In logistic regression, the AUC for HPV16/EPB41L3 methylation for all OPC cases was 0.82. Among early and late OPC cases, the AUC was 0.78 and 0.85, respectively. For early cases, 76% sensitivity was achieved, replicating results from our prior study, with a specificity of 65%, indicating room for improvement. The ability of HPV16/EPB41L3 methylation to distinguish OPC from healthy controls highlights its utility as a potential biomarker for OPC. However, the inability to predict early OPC better than late stage OPC indicates the need for additional biomarkers to improve screening performance.

29 January 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
BDBrittney L. Dickey
Brittney L. Dickey
RPRyan M. Putney
Ryan M. Putney
MSMichael Schell
Michael Schell
ABAnders Berglund
Anders Berglund
AAAntonio L. Amelio
Antonio L. Amelio
AGAnna R. Giuliano
Anna R. Giuliano
As oropharyngeal cancer (OPC) associated with human papillomavirus (HPV) increases in men, the need for a screening test to diagnose OPC early is crucial. This study agnostically identified differentially methylated CpG sites to identify additional biomarkers to improve screening for early OPC. DNA was extracted from oral gargles of 89 early cases and 108 frequency matched healthy controls, and processed for genome-wide methylation using the Illumina Infinium MethylationEPIC BeadChip. Selected sites were combined with our prior methylation data in the EPB41L3 gene (CpG sites 438, 427, and 425) and oral HPV16 and HPV18 status were considered as binary variables (positive/negative). Lasso regression identified CpG sites strongly associated with early OPC. ROC curves with AUC were generated. The panel was validated utilizing bootstrap resampling. Machine learning analyses identified 14 markers that are significantly associated with early OPC, including one EPB41L3 CpG site (438) and oral HPV16 status. A final model was trained on all available samples using the discovered panel and was able to predict early OPC compared with controls with an AUC of 0.970 on the training set. In the bootstrap validation sets, the average AUC was 0.935, indicating adequate internal validity. Our data suggest that this panel can detect OPC early, however external validation of this panel is needed. Further refinement of a panel of biomarkers to diagnose OPC earlier is urgently needed to prevent complex treatment of OPC and associated comorbidities, while reducing risk of recurrence. Prevention Relevance: This study identified biomarkers using genome-wide methylation to create a panel capable of discerning early oropharyngeal cancer (OPC) from those without OPC. Such a biomarker panel would be an effective tool to detect OPC early and prevent complications of treatment associated with later diagnosis.

2 April 2024
Verified
Other
Open access
PDF file
BDBrittney L. Dickey
Brittney L. Dickey
RPRyan M. Putney
Ryan M. Putney
MSMichael Schell
Michael Schell
ABAnders Berglund
Anders Berglund
AAAntonio L. Amelio
Antonio L. Amelio
AGAnna R. Giuliano
Anna R. Giuliano
Supplemental Figure 1 shows the number of non-zero coefficients per variable that was examined in the variable selection processing for the final biomarker panel.

2 April 2024
Verified
Other
Open access
PDF file
BDBrittney L. Dickey
Brittney L. Dickey
RPRyan M. Putney
Ryan M. Putney
MSMichael Schell
Michael Schell
ABAnders Berglund
Anders Berglund
AAAntonio L. Amelio
Antonio L. Amelio
AGAnna R. Giuliano
Anna R. Giuliano
Supplemental Figure 1 shows the number of non-zero coefficients per variable that was examined in the variable selection processing for the final biomarker panel.